Literature DB >> 1520630

Specific binding between human neutrophils and heparin.

C Leculier1, O Benzerara, N Couprie, A Francina, Y Lasne, E Archimbaud, D Fiere.   

Abstract

Heparin binding on polymorphonuclear leucocytes (PMNL) was characterized. Heparin binding was specific, rapid, saturable and reversible. One single class of heparin binding sites was found with a dissociation constant of 1.22 mumol/l and 7.7 x 10(6) sites per PMNL. The binding was independent of the anticoagulant activity of heparin. Heparin affinity chromatography on radio-iodinated cell lysates followed by polyacrylamide gel electrophoresis in the presence of sodium dodecylsulphate revealed a 130 kD heparin binding protein. Heparin binding was inhibited by disodium salt of ethylenediamine tetraacetic acid. Cell surface bound heparin was functionally inactive and did not affect the inactivation of thrombin by antithrombin III. Our study demonstrates that heparin interacts with PMNL by a cell-surface binding protein. These instructions could be consistent with the modifications of some PMNL functional properties in the presence of heparin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1520630     DOI: 10.1111/j.1365-2141.1992.tb08176.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.

Authors:  A Koenig; K Norgard-Sumnicht; R Linhardt; A Varki
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

2.  Heparin improves organ microcirculatory disturbances in caerulein-induced acute pancreatitis in rats.

Authors:  Marek Dobosz; Lucjanna Mionskowska; Stanislaw Hac; Sebastian Dobrowolski; Dariusz Dymecki; Zdzislaw Wajda
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

3.  Heparin and related drugs: beyond anticoagulant activity.

Authors:  Clive Page
Journal:  ISRN Pharmacol       Date:  2013-07-30

4.  HEPBURN - investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: study protocol for a multi-center randomized controlled trial.

Authors:  Gerie J Glas; Johannes Muller; Jan M Binnekade; Berry Cleffken; Kirsten Colpaert; Barry Dixon; Nicole P Juffermans; Paul Knape; Marcel M Levi; Bert G Loef; David P Mackie; Manu Malbrain; Marcus J Schultz; Koenraad F van der Sluijs
Journal:  Trials       Date:  2014-03-25       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.